Alnilam Pharmaceuticals had a trading volume of $374 million on February 19, ranking 317th among U.S. stocks on that day.

On February 19, 2026, Alnylam Pharmaceuticals (ALNY) had a trading volume of $374 million, ranking 317th among U.S. stocks for the day. The trading volume decreased by 2.13% compared to the previous day, with a daily trading volume of 1.1095 million shares.

Alnylam Pharmaceuticals (ALNY) rose 2.01% on February 19, 2026, closing at $339.37. The stock increased by 10.01% over the past five trading days, gained 0.39% for the entire month of February, and has fallen 14.66% since the beginning of the year. Over the past 52 weeks, it has increased by 35.47%.

*If the company’s listing duration is less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to cases where the listing duration is less than one month or fewer than five trading days).

Alnylam Pharmaceuticals, Inc. is a Delaware corporation established in May 2003. The company is a biopharmaceutical firm focused on developing new treatments based on RNA or RNA interference (RNAi). RNAi is a natural process within cells that selectively silences or regulates the expression of specific genes. Since many diseases are caused by abnormal activity of certain genes, the ability of RNAi to selectively silence genes offers a new approach to treating numerous human diseases. The company believes that drugs based on RNAi have the potential to become a new class of therapeutics, alongside small molecules, protein drugs, and antibody drugs. Leveraging established RNAi intellectual property and technical expertise, the company is developing biochemical methods to build a systematic platform that can be used to improve RNAi-based treatments for various diseases.